Drug profile · INN
selegiline hydrochloride
ZELAPAR
selegiline hydrochloride (ZELAPAR) is a monoamine oxidase b inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — selegiline hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
selegiline hydrochloride (ZELAPAR) is a monoamine oxidase b inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Monoamine oxidase B inhibitor
Primary target: Amine oxidase [flavin-containing] B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is selegiline hydrochloride?
selegiline hydrochloride (ZELAPAR) is a monoamine oxidase b inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for selegiline hydrochloride?
ZELAPAR is a marketed brand name for selegiline hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of selegiline hydrochloride?
selegiline hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.